ArticleKidney cancer (Clifton, Va.)2018

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.

Nicola J Lawrence et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.